Stockreport

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease

Viridian Therapeutics, Inc.  (VRDN) 
PDF - REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect -- Elegrobart Q4W and Q8W achieved cli [Read more]